MYC is a well-known oncogene that promotes proliferation, metabolic reprogramming, and chemotherapy resistance in GBM, making KDM4B a valuable therapeutic target, particularly in cases with high MYC amplification [108]. Here, KDM4B is linked to glioblastoma.